Completed PHASE1 INTERVENTIONAL 2-arm NCT03292302

Phase 1 Study of ELX-02 in Healthy Adults

A Phase 1a, Randomized, Double-blinded, Placebo-Controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ELX-02 in Healthy Adult Volunteers

Sponsor: Eloxx Pharmaceuticals, Inc.

Conditions Genetic Disease Nonsense Mutation

Interventions ELX-02 Placebo

Updated 9 times since 2017 Last updated: Aug 17, 2023 Started: Sep 26, 2017 Primary completion: Dec 15, 2017 Completion: Dec 15, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Genetic Disease and Nonsense Mutation and is currently completed. Eloxx Pharmaceuticals, Inc. leads this study, which shows 9 recorded versions since 2017 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Sep 2023 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — Sep 2023 [monthly]

Completed PHASE1
May 2020 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 4 earlier versions

Nov 2019 — May 2020 [monthly]

Completed PHASE1
Jun 2018 — Nov 2019 [monthly]

Completed PHASE1
Mar 2018 — Jun 2018 [monthly]

Completed PHASE1

Status: Recruiting → Completed
Oct 2017 — Mar 2018 [monthly]

Recruiting PHASE1

First recorded

Sep 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eloxx Pharmaceuticals, Inc.
SGS Life Sciences, a division of SGS Belgium NV

Data source: Eloxx Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Antwerp, Belgium